ALM 27134
Alternative Names: ALM-27134; Anti-human IL1RAP antagonist mAb; Anti-IL-1RAP mAb - Almirall S.A; ISB-880Latest Information Update: 25 Jul 2024
At a glance
- Originator Ichnos Sciences
- Developer Almirall S.A.
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 22 Jul 2024 Almirall plans a phase II trial for Autoimmune disorders (Parenteral) in the second half of 2024
- 30 Jan 2024 Glenmark and Ichnos enters into an alliance to form 'Ichnos Glenmark Innovation'
- 17 Oct 2022 Phase-I clinical trials in Autoimmune disorders in USA (Parenteral), before October 2022 (Ichnos Sciences pipeline, October 2022)